Merck Ruling A Wake-Up Call For Patent Owners Facing PTAB
Law360, New York (December 18, 2015, 9:44 PM EST) -- The Federal Circuit’s decision Thursday upholding a Patent Trial and Appeal Board ruling that dietary supplement patents licensed by Merck KGaA are invalid as obvious provides a clear illustration of the risks for patents in inter partes reviews and how tough it is to get PTAB decisions overturned on appeal, attorneys say.
The initial PTAB decision in 2014 that Merck’s arguments for why the patents were not obvious could not overcome challenger Gnosis SpA’s evidence of obviousness is an indication that the board will be very closely scrutinizing the defenses used by patent owners in inter partes review, according to attorneys...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!